Added to YB: 2026-06-08
Pitch date: 2026-06-04
GRF.MC [neutral]
Grifols, S.A.
-0.64%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Market Cap
EUR 5.5B
Pitch Price
EUR 9.12
Price Target
N/A
Dividend
3.31%
EV/EBITDA
9.62
P/E
14.85
EV/Sales
2.27
Sector
Biotechnology
Category
N/A
Grifols (GRF Spain): ' Whoops'
GRF.MC (update): Bloomberg error wrongly tied Alpha-1 delay to key Phase III SPARTA trial (300+ pts, IV Prolastin-C); company clarified delay is for smaller PK/safety SubQ vs IV study. SPARTA readout still late 2026-early 2027. Rising competition (CSL, Takeda, Sanofi recombinant, gene-editing) + leverage/execution concerns keep setup challenging.
Read full article (2 min)